Physician profile
David P Lynch
NPI 1013987049
$620.02
in general payments reported to CMS, 2019-2025
11 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $122 · 2024: $307 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $620.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $191.31 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $115.09 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $104.75 | 2023-2024 | |
| Lilly USA, LLC | $39.93 | 2024-2025 | Mounjaro |
| Glaxosmithkline, LLC. | $35.38 | 2023-2024 | Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $32.50 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $29.30 | 2025 | Airsupra |
| E.R. Squibb & Sons, L.L.C. | $19.33 | 2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $19.18 | 2025 | |
| Merck Sharp & Dohme LLC | $16.82 | 2024 | M-M-R II, Gardasil 9, Gardasil |
| Amgen INC. | $16.43 | 2024 | Prolia, Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.